Abe K, Terakawa H, Takanashi M, Watanabe Y, Tanaka H, Fujita N, Hirabuki N, Yanagihara T
Department of Neurology, Osaka University Graduate School of Medicine, Osaka, Japan.
Brain Res Bull. 2000 Aug;52(6):589-95. doi: 10.1016/s0361-9230(00)00321-x.
We studied cerebral metabolism in 82 patients with nonfamilial parkinsonism, including Parkinson's disease (PD; n = 23), progressive supranuclear palsy (PSP; n = 12), corticobasal degeneration (CBD; n = 19), multiple systemic atrophy (MSA; n = 18) and vascular parkinsonism (VP; n = 10) by using proton magnetic resonance spectroscopy ((1)H-MRS), which allowed noninvasive measurement of signal intensities from N-acetylasparate (NAA), choline-containing compounds (CHO) and creatine plus phosphocreatine (CRE). As compared to normal controls, patients with PSP, CBD, MSA and VP, but not PD, had significant reduction of the NAA/CRE ratio in the frontal cortex, whereas patients with PSP, CBD, MSA and PD, but not VP, had significant reduction of the NAA/CRE ratio in the putamen. Patients with CBD had significant reduction of the NAA/CRE ratio in the frontal cortex and putamen as compared to patients with PD, MSA and VP. Patients with PSP showed a significant reduction of the NAA/CRE ratio in the putamen as compared with patients with PD and MSA. Patients with CBD showed clear asymmetry in the putamen as compared to controls and other patients. The reduction of the NAA/CRE ratio in the putamen correlated well with the severity of parkinsonism. (1)H-MRS may be useful in monitoring patients with various types of parkinsonism.
我们使用质子磁共振波谱（(1)H-MRS）对82例非家族性帕金森综合征患者的脑代谢进行了研究，这些患者包括帕金森病（PD；n = 23）、进行性核上性麻痹（PSP；n = 12）、皮质基底节变性（CBD；n = 19）、多系统萎缩（MSA；n = 18）和血管性帕金森综合征（VP；n = 10），(1)H-MRS可对N-乙酰天门冬氨酸（NAA）、含胆碱化合物（CHO）以及肌酸加磷酸肌酸（CRE）的信号强度进行无创测量。与正常对照组相比，PSP、CBD、MSA和VP患者（而非PD患者）额叶皮质的NAA/CRE比值显著降低，而PSP、CBD、MSA和PD患者（而非VP患者）壳核的NAA/CRE比值显著降低。与PD、MSA和VP患者相比，CBD患者额叶皮质和壳核的NAA/CRE比值显著降低。与PD和MSA患者相比，PSP患者壳核的NAA/CRE比值显著降低。与对照组和其他患者相比，CBD患者壳核存在明显的不对称性。壳核中NAA/CRE比值的降低与帕金森综合征的严重程度密切相关。(1)H-MRS可能有助于监测各类帕金森综合征患者。
